Steup, Christoph and Kennel, Kilian and Neurath, Markus F. and Fichtner-Feigl, Stefan and Greten, Florian (2025) Current and emerging concepts for systemic treatment of metastatic colorectal cancer. GUT, 74 (12). pp. 2070-2095. ISSN 0017-5749, 1468-3288
Full text not available from this repository. (Request a copy)Abstract
Colorectal cancer (CRC) is one of the most common malignant cancers and its incidence is steadily rising particularly in young patients. While screening measures and the widespread availability of surgical treatment have led to an impressive improvement of prognosis within the overall CRC population, patients with metastatic CRC still face 5-year survival rates of around 10-25%. Despite continuous development of new systemic treatment strategies that include cytotoxic chemotherapy and targeted therapy, most patients with metastatic CRC eventually progress. However, a small proportion of patients with mismatch repair-deficient or microsatellite unstable CRC responds exceptionally well to treatment with immune checkpoint inhibitors, thereby proving that CRC is in principle amenable to immunotherapy and showing that long-term disease stabilisation can be achieved even in metastasised stages. However, the reasons for the lack of response to immunotherapy in the vast majority of CRC cases remain to be elucidated. Yet, recent evidence suggests that the tumour stroma, which includes non-immune cells in the colorectal tumour microenvironment, mediates immunosuppressive mechanisms that prevent effective immunotherapy. These findings open new avenues for the development of advanced immunotherapies for CRC. In this review, we summarise major developments in the systemic therapy of CRC within the last couple of decades, provide an overview of emerging and soon-to-be implemented therapeutic strategies and present concepts from clinical and preclinical research to manipulate tumour cells and the tumour stroma to sensitise microsatellite stable colorectal tumours to immunotherapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ANTIBODY-DRUG CONJUGATE; POTENTIAL THERAPEUTIC TARGET; CLINICAL-PRACTICE GUIDELINE; SACITUZUMAB GOVITECAN; TGF-BETA; 1ST-LINE TREATMENT; SINGLE-ARM; PHASE-I; TRASTUZUMAB; BREAST; COLORECTAL CANCER |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 01 Oct 2026 07:29 |
| Last Modified: | 01 Oct 2026 07:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67410 |
Actions (login required)
![]() |
View Item |

